Drug Development · global
Targeting Potassium Channels in Immune Cells, ZP9830 Completes Phase 1 Multiple-Dose Testing
Zealand Pharma’s Kv1.3 blocker showed preliminary signs of tolerability in a four-week trial in healthy participants. A study in patients with psoriasis, already underway, will next examine whether this immunomodulatory strategy can improve disease.
Quieting the immune cells that drive chronic inflammation while preserving the body’s ability to fight infections is a goal of new drugs for autoimmune diseases. Danish biotechnology company Zealand Pharma announced on October 19 that its investigational drug ZP9830 had completed the multiple ascending dose portion of a Phase 1 trial, with preliminary results supporting further testing. Whether it can improve patients’ disease remains a question for subsequent studies.
The randomized, double-blind, placebo-controlled study enrolled 32 healthy men and women to assess the safety and tolerability of repeated dosing, as well as pharmacokinetics, including how the drug is absorbed and cleared in the human body. Treatment lasted four weeks, with safety follow-up continuing through Day 41, so the current data primarily reflect short-term use.
According to the summary released by the company, adverse events occurring during treatment among participants receiving ZP9830 were all mild, none were classified as serious adverse events, and no safety findings limited dose escalation. There were also no clinically meaningful safety abnormalities in vital signs, electrocardiograms, physical examinations, or laboratory tests. The company said the pharmacokinetic results support longer trials, but the announcement did not provide complete numerical data or comparisons across dose groups.
ZP9830 targets the Kv1.3 potassium channel. According to the company, these channels show increased expression on effector memory T cells, a population of immune cells that can release pro-inflammatory signals and contribute to autoimmune responses and tissue damage. The rationale for blocking Kv1.3 is to suppress the activity of these cells while preserving other immune defense functions as much as possible. However, short-term safety data from healthy participants cannot yet establish the potential for this selective modulation.
The next step in the research has already moved into patients. A report from S&P Capital IQ published through MarketScreener stated that Zealand has initiated a Phase 1b trial in plaque psoriasis, with a design that includes efficacy endpoints. This will move the research beyond asking whether humans can tolerate the drug to examining whether immune modulation can translate into disease improvement. The company also plans to initiate a Phase 2 trial in another autoimmune disease in the first half of 2027, but the disease was not disclosed in this announcement.
The completed work covers the multiple ascending dose portion; the overall Phase 1 study is still evaluating one additional single administration. The current results come from a preliminary summary released by the company, with a small number of participants, limited follow-up, and no evidence yet of efficacy in patients from this multiple-dose testing. ZP9830 has established a basis for continued investigation; long-term safety, actual efficacy, and whether immune defenses can be preserved still need to be verified individually in patients and over longer treatment periods.